Plaque psoriasis is the most common type of psoriasis, with approximately 80 percent to 90 percent of patients with psoriasis developing plaques. On July 22, 2020, the U.S. Food and Drug Administration approved Wynzora® cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) for the treatment of plaque psoriasis in adult patients.
Wynzora® cream marks the first cream formulation of a vitamin D based treatment (calcipotriene) and a corticosteroid (betamethasone dipropionate). Using proprietary PAD™ Technology, researchers developed a way to enable stability of both treatments in a cream formulation that is meant to be convenient for patients to use.
Data from phase 3 trials of Wynzora® cream showed it to have statistically significant treatment efficacy as well as favorable patient-reported outcomes, compared to another calcipotriene and betamethasone dipropionate topical treatment.
Manufacturer, MC2 Therapeutics, is also investigating drug candidates for other indications such as atopic dermatitis.
Driving discovery, creating community
For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.